Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages

Annals of the Rheumatic Diseases

Volumn 59, Issue 1, 2000, Pages 26-31

  Itonaga, I ^a   Sabokbar, A ^a   Murray, D W ^a   Athanasou, N A ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NUFFIELD ORTHOPAEDIC CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; CD14 ANTIGEN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; VITRONECTIN RECEPTOR;

ADULT; AGED; ARTHROPLASTY; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MACROPHAGE; MALE; MEMBRANE; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROSTHESIS LOOSENING; STROMA CELL;

AGED; AGED, 80 AND OVER; ARTHROPLASTY, REPLACEMENT, HIP; CARRIER PROTEINS; CELL COMMUNICATION; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLYCOPROTEINS; HUMANS; MACROPHAGES; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; OSTEOCLASTS; OSTEOPROTEGERIN; PROSTHESIS FAILURE; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 0034107339     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.59.1.26     Document Type: Article

References (50)

1. 1 Bullough PG, DiCarlo EF, Hansraj KK, Neves MC. Pathologic studies of total joint replacement. Orthop Clin North Am 1988;19:611-25.
2. 2 Lennox DW, Schofield BW, McDonald DF, Riles LH. A histologic comparison of aseptic loosening of cemented, press-fit and biologic ingrowth prostheses. Clin Orthop 1987;225:171-91.
3. 3 Revell PA. Tissue reactions to joint prostheses and the products of wear and corrosion. In: Berry C, ed. Current trends in pathology. Berlin: Springer-Verlag: 1982:73-101.
4. 4 Harris WH. Osteolysis and particle disease in hip replacements (a review). Acta Orthop Scand 1994;65:113-23.
5. 5 Harris WH. The problem is osteolysis. Clin Orthop 1995;311:46-53.
6. 6 Goodman SB, Chin RC. Prostaglandin E2 levels in the membrane surrounding bulk and particulate polymethylmethacrylate in the rabbit tibia: a preliminary study. Clin Orthop 1990;257:305-9.
7. 7 Goodman SB, Chris RC, Chiou SS, Schurman DJ, Woolson ST, Masada MP. A clinical-pathological-biochemical study of the membrane surrounding loosened and non loosened total hip arthroplasties. Clin Orthop 1989;244:182-7.
8. 8 Murray DW, and Rushton N. Macrophages stimulate bone resorption when they phagocytose particles. J Bone Joint Surg Br 1990;72-B:988-92.
9. 9 Jiranek WA, Machado M, Jasty M, Jervevar D Wolfe HJ, Goldring SR, et al. Production of cytokines around loosened cemented acetabular components. J Bone Joint Surg Am 1993;75-A:863-79.
10. 10 Kim KJ, Rubash HE, Wilson SC, D'Antonio JA, McClain EJ. A histologic and biochemical comparison of the interface tissues in cementless and cemented hip prostheses. Clin Orthop 1993;287:142-52.
11. 11 Quinn JM, Joyner C, Triffitt JT, Athanasou NA. PMMA-induced inflammatory macrophages resorb bone. J Bone Joint Surg Br 1992;74-B:652-8.
12. 12 Quinn JMW, Sabokbar A, NA Athanasou. Cells of the mononuclear phagocyte series differentiate into osteoclastic lacunar bone resorbing cells. J Pathol 1996;179:106-11.
13. 13 Udagawa N, Takahashi N, Akatsu T, Tanaka H, Sasaki T, Nishihara T, et al. Origin of osteoclasts: Mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci USA 1990;87:7260-4.
14. 14 Sabokbar A, Fujikawa Y, Neale S, Murray DW, Athanasou NA. Human arthroplasty macrophages differentiate into osteoclastic bone resorbing cells. Ann Rheum Dis 1997;56: 414-20.
15. 15 Fujikawa Y, Quinn JMW, Sabokbar AS, McGee JOD, Athanasou NA. The human mononuclear osteoclast precursor circulates in the monocyte fraction. Endocrinology 1996; 137:4058-60.
16. 16 Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S-I, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and identical to TRANCE-RANKL. Proc Natl Acad Sci USA 1998;95:3597-602.
17. 17 Lacey DL, Timms E, Tan H-L, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
18. 18 Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1998;89:309-19.
19. 19 Tsuda E, Goto M, Mochizuki S-I, Yano K, Kobayashi F, Morinaga T, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997;234:137-42.
20. 20 Yasuda H, Shima N, Nakagawa N, Mochizuki S-I, Yano K, Fujise N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998;139:1329-37.
21. 21 Partridge N, Alcorn D, Michelangeli V, Kemp E, Ryan G, Martin TJ. Functional properties of hormonal responsive cultured normal and malignant rat osteoblastic cells. Endocrinology 1981;108:213-19.
22. 22 Andersson G, Ek-Rylander B, Minkin C. Acid phosphatases. In: Rifkin BR, Gay CV, eds. Biology and physiology of the osteoclast. Boca Raton: CRC Press, 1992:55-80.
23. 23 Gatter KC, Falini B, Mason DY. The use of monoclonal antibodies in histological diagnosis, In: Anthony PP, Mac Sween RNM, eds. Recent advances in histopathology, no 12. Edinburgh: Churchill Livingstone, 1984:35-67.
24. 24 Horton MA, Lewis D, McNulty K, Pringle JAS, Chambers TJ. Monoclonal antibodies to osteoclastomas (giant cell bone tumours): definition of osteoclast specific cellular antigens. Cancer Res 1985;45:5663-9.
25. 25 Athanasou NA, Quinn J. Immunophenotypic differences between osteoclasts and macrophage polykaryons: immunohistological distinction and implications for osteoclast ontogeny and function. J Clin Pathol 1990;43:997-1004.
26. 26 Schlossman SF, Boumsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C, et al. Leucocyte typing V: white cell differentiation antigens. Oxford: Oxford University Press, 1995.
27. 27 Boyde A, Ali NN, Jones SJ. Resorption of dentine by isolated osteoclasts in vitro. Br Dent J 1984; 156:216-20.
28. 28 Amstutz HC, Campbell P, Kossovsky N, Clarke IC. Mechanisms and clinical significance of wear debris-induced osteolysis. Clin Orthop 1992;276:7-18.
29. 29 Horowitz SM, Purdon MA. Mechanisms of cellular recruitment in aseptic loosening of prosthetic joint implants. Calcif Tissue Int 1995;57:301-5.
30. 30 Malcolm AJ. The pathology of long-standing cemented total hip replacement in Charnley's cases. J Bone Joint Surg Br 1988;70-B:153-6.
31. 31 Santavirta S, Hoikka V, Eskola A, Kontinnen Y, Paavilainen T, Tallroth V. Aggressive granulomatous lesions in cementless total hip arthroplasty. J Bone Joint Surg Br 1990;72-B: 980-4.
32. 32 Santavirta S, Konttinen TY, Bergroth V, Eskola A, Tallroth K, Lindholm TS. Aggressive granulomatous lesions associated with hip arthroplasty: immunopathological studies. J Bone Joint Surg Am 1990;72-A:252-8.
33. 33 Quinn JMW, McGee JO'D, Athanasou NA. Cellular and hormonal factors influencing monocyte differentiation to osteoclastic bone resorbing cells. Endocrinology 1994;134: 2416-23.
34. 34 Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997;272:25190-4.
35. 35 Wong BR, Josien R, Lee SY, Sauter B, Li H-L, Stainman RM, et al. TRANCE (tumor necrosis factor (TNF)-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997;186:2075-80.
36. 36 Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997;390:175-9.
37. 37 Quinn JMW, Elliott J, Gillespie MT, Martin TJ. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 1998; 139:4424-7.
38. 38 Matsuzaki K, Udagawa N, Takahashi N, Yamaguchi K, Yasuda H, Shima N, et al. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun 1998;246:199-204.
39. 39 Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1998;188:997-1001.
40. 40 Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 1998;253:395-400.
41. 41 Haynes DR, Potter AE, Atkins GJ, Findlay DM, Crotti T, Howie DW, et al. Metal particles stimulate expression of regulators of osteoclast development including osteoclast differentiation factor (RANKL/TRANCE), osteoprotegerin and M-CSF. 45th Annual Meeting of Orthopaedic Research Society, Anaheim, California. Trans Orthop Res Soc 1999;24:244.
42. 42 Vidal ONA, Brändström H, Jonsson KB, Ohlsson C. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. J Endocrinol 1998;159:191-5.
43. 43 Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998;247:610-15.
44. 44 Yun TJ, Chaudhary PM, Shu GL, Frazer JK, Ewings MK, Schwartz SM, et al. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol 1998;161:6113-21.
45. 45 Brändström H, Jonsson KB, Vidai O, Ljunghall S, Ohlsson C, Ljunggren Ö. Tumor necrosis factor-α and -β upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells. Biochem Biophys Res Commun 1998;248:454-7.
46. 46 Vidal ONA, Sjögren K, Eriksson BI, Ljurggren Ö, Ohlsson C. Osteoprotegerin mRNA is increased by Interleukin-1α in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. Biochem Biophys Res Commun 1998; 248:696-700.
47. 2 in human bone marrow stroma cells. Biochem Biophys Res Commun 1998;247:338-41.
48. 2, or parathyroid hormone in the microenvironment of bone. Biochem Biophys Res Commun 1998;246:337-41.
49. 49 Horwood NJ, Elliott J, Martin TJ, Gillespie MT. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 1998;139:4743-6.
50. 3, by synovial fluid macrophages in arthritic disease. Ann Rheum Dis 1989;48:723-9.